Inmarsat set for FTSE demotion in quarterly review
Satellite communications company Inmarsat could be pushed out of the FTSE 100 by Hikma Pharmaceuticals in June, according to the FTSE Russell.
CMC Markets Plc
325.50p
11:39 15/11/24
Countryside Partnerships
229.80p
16:40 11/11/22
FTSE 100
8,076.39
11:35 15/11/24
FTSE 250
20,517.30
11:35 15/11/24
FTSE 350
4,461.34
11:35 15/11/24
FTSE All-Share
4,419.43
11:35 15/11/24
Hikma Pharmaceuticals
1,800.00p
11:35 15/11/24
Inmarsat
544.40p
07:56 04/12/19
Interserve
6.05p
16:54 15/03/19
Jimmy Choo
230.00p
16:30 30/10/17
Metro Bank Holdings
90.80p
11:29 15/11/24
Mobile Telecommunications
1,979.89
16:59 24/01/22
Personal Goods
13,400.84
11:34 15/11/24
Pharmaceuticals & Biotechnology
19,358.93
11:34 15/11/24
Support Services
10,952.40
11:35 15/11/24
Zigup
361.00p
11:34 15/11/24
Changes from the latest quarterly review of the FTSE 100, to be announced on Wednesday, will take place on Friday 17 June.
Earlier this month, Inmarsat shares tanked after it cut its full-year revenue guidance by $50m to a range of $1.175bn - $1.250bn amid an ongoing recession in global maritime and energy markets.
The company said first-quarter earnings before interest, tax, depreciation and amortisation fell 6% to $166.2m, while revenue for the quarter fell 2% from the previous year to $298.6m.
Hikma was knocked out of the FTSE 100 back in March and replaced by Mediclinic International, the private healthcare group known as Al Noor before it merged with Mediclinic in February.
Interserve, Jimmy Choo, Northgate and Melrose Industries were among the FTSE 250 companies at risk of being demoted to the FTSE Small Cap Index.
Countryside Properties, Metro Bank and CMC Markets, meanwhile, were among those that could be added to the FTSE 250.